These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 19527481

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ.
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [Abstract] [Full Text] [Related]

  • 3. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
    Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, le Devehat C, Romero E, Liebl A.
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
    [Abstract] [Full Text] [Related]

  • 4. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W, Ji Q, Zhu D, Yang J, Chen L, Liu Z, Yu D, Yan L.
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [Abstract] [Full Text] [Related]

  • 5. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
    Ashwell SG, Gebbie J, Home PD.
    Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
    [Abstract] [Full Text] [Related]

  • 6. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 7. Comparison of thrice daily 'high' vs. 'medium' premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes.
    Ejskjaer N, Rasmussen M, Kamp N, Lindholm A, Christiansen JS.
    Diabetes Obes Metab; 2003 Nov; 5(6):438-45. PubMed ID: 14617230
    [Abstract] [Full Text] [Related]

  • 8. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT.
    Strojek K, Bebakar WM, Khutsoane DT, Pesic M, Smahelová A, Thomsen HF, Kalra S.
    Curr Med Res Opin; 2009 Dec; 25(12):2887-94. PubMed ID: 19821654
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus.
    McSorley PT, Bell PM, Jacobsen LV, Kristensen A, Lindholm A.
    Clin Ther; 2002 Apr; 24(4):530-9. PubMed ID: 12017398
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70.
    Schernthaner G, Kopp HP, Ristic S, Muzyka B, Peter L, Mitteregger G.
    Horm Metab Res; 2004 Mar; 36(3):188-93. PubMed ID: 15057674
    [Abstract] [Full Text] [Related]

  • 13. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI, Străchinariu R, Farcaşiu E, Milicevic Z, Teodorescu G.
    Rom J Intern Med; 2003 Mar; 41(2):153-62. PubMed ID: 15526500
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
    Bi YF, Zhao LB, Li XY, Wang WQ, Sun SY, Chen YH, Hong J, Su TW, Liu JM, Ning G.
    Chin Med J (Engl); 2007 Oct 05; 120(19):1700-3. PubMed ID: 17935674
    [Abstract] [Full Text] [Related]

  • 17. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
    Dashora UK, Sibal L, Ashwell SG, Home PD.
    Diabet Med; 2007 Apr 05; 24(4):344-9. PubMed ID: 17298589
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
    Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R.
    Clin Ther; 2005 Apr 05; 27 Suppl B():S75-88. PubMed ID: 16519039
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.